Adaptimmune Therapeutics plc American Depositary Shares (ADAP)

Questex's Fierce Pharma Week will feature celebrities like Jamie-Lynn Sigler, James Van Der Beek, and Selma Blair sharing personal health stories, alongside pharmaceutical industry leaders discussing innovation and patient experiences.

The FDA is expected to make several landmark decisions in Q3, including approvals for treatments for schizophrenia, PTSD, and liver disease. These decisions could be impacted by recent biotechnology acquisitions.

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates. Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback. Marvell Technology shares dipped 9.6% to $76.91 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Ainos, Inc. (NASDAQ: AIMD) jumped 140% to $2.6899 after dipping 18% on Thursday. Psyence Biomedical Ltd. (NASDAQ: PBM) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study. Safe and Green Development Corporation (NASDAQ: SGD) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder. CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients. Willdan Group, Inc. (NASDAQ: WLDN) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years. The Joint Corp. (NASDAQ: JYNT) gained 29% to $11.80 following fourth-quarter results. Smith & Wesson Brands, Inc. (NASDAQ: SWBI) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results. Research Frontiers Incorporated ...

The company bulks up its pipeline by regaining the rights to two of its clinical programs.